In comparison with earlier studies
H igh-grade prostatic intraepithelial neoplasia (HGPIN) has long been considered a precursor of prostate carcinoma. 15, 18, 21 Recent studies have shown the incidence of prostatic adenocarcinoma (PCa) in needle biopsies obtained after a diagnosis of isolated HGPIN to be 28.8% to 30.5%. 2, 7 When only those studies with 50 or more patients are analyzed, the mean risk of cancer on repeat biopsy is only 25.3%. 4 This rate is significantly lower than that encountered in several prior studies 1, 3, 8, 12, 17, 19, 23 and is not higher than the expected incidence of prostate cancer after an initial negative biopsy (26.2%). 6 There are conflicting data in terms of the relationship between the number of cores involved by PIN and the subsequent risk of finding adenocarcinoma on follow-up (F/U) biopsies. 2, 6, 11, 16 However, these studies have not specifically examined the issue as to whether men with an initial diagnosis of widespread HGPIN are at increased likelihood of subsequently diagnosed carcinoma.
MATERIALS AND METHODS
The surgical pathology database at The Johns Hopkins Hospital was searched for prostate needle biopsies with a diagnosis of HGPIN in a minimum of 4 cores. A total of 73 cases were identified in the period between 1994 and 2005. Sixty-four of the cases were from the consultation files of one author (J.I.E.). Of the 73 men, 41 had at least 1 F/U biopsy procedure and represent the group in this study.
No statistically significant difference in age or number of initial cores was seen between the 41 patients that were included in the study and the 32 patients who were excluded from further analysis because of the lack of a F/U sampling procedure (mean age: 66.8 vs. 68.2 y, respectively, P = 0.3; mean number of initial cores: 10.4 for both group, P = 0.95). The 2 groups differed in prostate-specific antigen (PSA) levels before initial biopsy. PSA levels were higher in the 41 patients with subsequent F/U biopsy (mean 14.1 ng/mL; median 8.2 ng/mL; range 2.5 to 90 ng/mL) compared with the 32 patients who lacked a F/U sampling procedure (mean 3.5 ng/mL; median 3.3 ng/mL; range 0.5 to 8.5 ng/mL) (P = 0.0007).
Standard accepted criteria were used for the diagnosis of HGPIN. 15 Obtained F/U data included the date, nature, and frequency of any subsequent prostate sampling procedure using a data collection form designed for the study. The form was sent to the original pathologist and or urologist on all outside cases that were reviewed in consultation. Four diagnoses were recorded on all F/U samples: PCa, HGPIN, HGPIN with adjacent small atypical glands (PINATYP), and benign prostatic tissue (BPT). Patients were then grouped into 3 groups: PCa, HGPIN/PINATYP, and BPT groups.
Statistical software (STATA, College Station, TX) was used for data analysis. The Student t test was used to assess potential differences in age and number of cores sampled between those men with and without repeat biopsy. Among men who had a repeat biopsy, differences between subgroups were determined using w 2 test.
RESULTS

Patient Demographics and F/U Procedures
The average age of the 41 patients at the time of initial widespread HGPIN diagnosis was 66.8 years. The mean ages for patients with subsequently diagnosed PCa, HGPIN/PINATYP, and BPT diagnoses were 68 (range: 58 to 77), 67.5 (range: 56 to 79), and 64.2 (range: 54 to 69) years, respectively.
By study design, all patients underwent at least 1 F/U sampling procedure. Three patients were followed up solely by a transurethral resection (TURP). The remaining 38 patients had at least 1 repeat needle biopsy set and their F/U was conducted as follows: 1 repeat needle biopsy in 34 patients, 2 repeat biopsies in 3 patients, 1 repeat biopsy set followed by a TURP in 1 patient and 2 TURP procedures in another patient. F/U procedures were performed during a period of 1 to 41 months with a mean of 11 months. The mean and median number of cores per initial biopsy were 10.6 and 10, respectively (range 5 to 16). The mean and median number of cores per F/U biopsy were 10.4 and 10, respectively (range 6 to 16).
PSA Levels Before Initial Biopsy and Likelihood of Carcinoma on F/U PSA levels before initial biopsy were available in 24 of our 41 patients including 9 patients who were subsequently diagnosed with carcinoma. The likelihood of identifying carcinoma on F/U biopsy did not seem to correlate with PSA levels before initial biopsy. As shown in Table 1 , the likelihood of subsequent diagnosis of carcinoma was 50%, 27%, and 44% in patients with initial PSA levels of (2 to <4 ng/mL), (4 to <10 ng/mL), and Z10 ng/mL, respectively (P = 0.4). The mean PSA level before initial HGPIN biopsy in the 3 groups with BPT, HGPIN/PINATYP, and carcinoma on F/U biopsies were 14.3 (range: 3 to 53), 18.7 (range 2.6 to 90), and 9.7 (range: 2.5 to 27.8 ng/mL), respectively.
Histologic Findings
Overall the likelihood for finding PCa on F/U was 39% (16/41) ( Table 2 ). In 5 patients (12.2%), F/U biopsies revealed PINATYP. An additional 9 patients (22%) continued to show HGPIN. The remaining 11 patients (26.8%) revealed BPT on F/U.
All but 1 of the prostate cancers were identified on the first F/U procedure with the remaining patients diagnosed on a TURP after a negative repeat F/U biopsy. Patients who were Z70 years of age at the time of their initial biopsy had a statistically significant higher rate of PCa or HGPIN/PINATYP on repeat biopsy compared with younger patients (P = 0.02) ( Table 3 ). The incidence of prostate cancer on repeat biopsy was 55% in men 70 years and older opposed to 33% in men who were <70 years of age at the time of initial biopsy.
A statistically significant relationship was noted between the number of cores on initial biopsy and the diagnosis on F/U. Patients with a fewer number of cores on initial biopsy were more likely to be diagnosed with PCa as opposed to HGPIN/PINATYP on F/U (P = 0.015) ( Table 2 ). Other factors such as the number of F/U procedures, number of cores per F/U biopsy, interval length between initial, and repeat biopsy did not affect the likelihood of finding carcinoma on repeat biopsy ( Table 2 ). All but 1 of the prostatic carcinomas were diagnosed within 2 years from the initial biopsy with 10 rendered within the first year. The majority (11/16) of adenocarcinomas were of Gleason score 6. Gleason scores in remaining cases were distributed as follow: 5 (n = 1), 7 (n = 3), and 9 (n = 1).
The 5 patients in our study with more than 1 F/U procedure included the above-mentioned single patient with PCa diagnosed on TURP after a first negative repeat biopsy. The remaining 4 had the following results: one revealed HGPIN on the first and second repeat biopsy, a second revealed PINATYP followed by HGPIN, a third revealed HGPIN followed by PINATYP. The fourth patient revealed PINATYP on the first biopsy procedure with the subsequent 2 TURP procedures yielding only BPT.
DISCUSSION
The significance of finding solely HGPIN on biopsy of prostate is related to its potential association with PCa on subsequent biopsy. Initial studies suggested the estimated likelihood for finding PCa on repeat biopsy to be in the range of 27% to 79%. 1, 3, 12, 20, 23, 24 The range of cancer risk demonstrated in the larger and more recent studies is 23% to 32.2% 2, 6, 11, 17 with the 2 most recent among these series showing a 28.8% and 30.5% risk. 2, 6 When only those studies with 50 or more patients are analyzed, the mean approaches the median with a risk of 25.3%. The reported likelihood of finding cancer after a diagnosis of HGPIN on needle biopsy has decreased in the contemporary era. Of the 22 studies published in the year 2000 or later on the likelihood of finding cancer after a needle diagnosis of HGPIN, 16 (73%) report the likelihood to be below the median risk of 24.1%. 4 Nine publications have compared in the same study the risk of cancer after a needle biopsy diagnosis of HGPIN to the risk of cancer after a benign diagnosis on needle biopsy. 4 Seven studies showed no statistically significant difference in the risk of cancer on repeat biopsy after an HGPIN diagnosis compared with rebiopsy after a benign diagnosis. 4 Speculations on potential causes for this apparent overall decline in likelihood of subsequent diagnosis of carcinoma include: increased sampling with currently adopted extended biopsy approach and possibly a lower detection rate of smaller cancers accompanying HGPIN given the overall increasingly higher rate of detecting smaller and lower stage prostatic cancers. 2, 6, 16, 22 A recent study by Herawi et al 7 on a large group of men documented the significance of biopsy sampling in the detection of cancer after a diagnosis of HGPIN. In cases with 6 core biopsies for both the initial and rebiopsy, the risk of cancer after HGPIN was 14.1% (20/142). With an initial 6 core biopsy and >8 core repeat biopsy, the risk increased to 31.9% (36/113). With >8 core biopsy sampling for both the initial and repeat biopsies, the risk for cancer was 14.6% (37/253). The above findings can be explained by the following: relatively poor sampling (6 cores) on the initial biopsy misses associated cancers resulting in only HGPIN on the initial biopsy; relatively poor sampling on rebiopsy also results in a relatively low risk of cancer on rebiopsy. With poor sampling on the initial biopsy and better sampling on rebiopsy, some of these initially missed cancers are detected on rebiopsy yielding a higher detection of cancer. Sampling more extensively on the initial biopsy detects many associated cancers, such that when only HGPIN is found they often represent isolated HGPIN; therefore, rebiopsy even with good sampling does not detect many additional cancers. Interestingly, our current finding that patients with a fewer number of cores on initial biopsy were more likely to be diagnosed with PCa as opposed to HGPIN/ PINATYP on F/U would support such a line of reasoning. Regardless of the etiology behind it, the declining likelihood rate for detecting cancer in this group of patients has brought into question the absolute need for rebiopsy after an initial diagnosis of HGPIN. 6, 13, 16 The declining likelihood rate has prompted others to recommend delaying the repeat biopsy allowing for a longer interval than the originally recommended 6 to 12 months. 14 An issue that remains is whether routine repeat biopsy should be performed several years after a HGPIN diagnosis, and if so how often and when. As clinical findings and morphologic patterns of HGPIN have not consistently stratified which men with HGPIN are at increased risk of being diagnosed with cancer, identifying a subset of HGPIN patients with a higher subsequent PCa risk would be of great value in providing guidance for the currently evolving F/U recommendations. 4 Prior studies addressing the relationship between number of cores containing HGPIN on initial biopsy and the likelihood of finding carcinoma on subsequent biopsy have lead to some discordant conclusions. 2, 6, 11, 16 The study by Kronz et al 11 revealed a statistically significant correlation between the number of HGPIN containing cores and likelihood of subsequent PCa. Bishara et al 2 also demonstrated a trend for a higher likelihood for adenocarcinoma in patients with 2 or more cores containing HGPIN on initial biopsy compared with those with less than 2. Several other studies including studies by Gokden et al 6 and Naya et al 16 failed to show a statistically significant correlation between the number of HGPIN cores and subsequent likelihood of detecting PCa. However, these studies have not examined the relatively uncommon situation when widespread HGPIN is found on needle biopsy. We chose to quantify HGPIN on biopsy based on the number of involved cores, because it lends itself to comparison with other studies which have used this method and is more reproducible than alternative measurements. Furthermore, other measurements, such as number of HGPIN glands, percentage of the core involved by HGPIN, or millimeters of the core involved by HGPIN, are not likely to be adopted in clinical practice.
Our study demonstrated a 39% likelihood of finding PCa after the initial identification of widespread (4 or more cores) HGPIN. This likelihood rate is higher than the overall risk of adenocarcinoma (23% to 32.2%) after HGPIN that has been previously reported by our group and others. 2, 6, 11, 17 Furthermore, the 39% likelihood rate stands in significant contrast to the baseline risk of finding adenocarcinoma on a repeat biopsy after an initial benign diagnosis. The latter have been estimated to be in the range of 19% to 26.2% 6, 9 making the likelihood of finding adenocarcinoma in our patients with initial widespread HGPIN approximately one and half to two times higher than that expected after an initially benign biopsy. Such likelihood increment would support a recommendation for a repeat biopsy in this subset of HGPIN patients. On the basis of our finding that all but 1 of the adenocarcinoma diagnoses were obtained at the first F/U procedure, the absolute need for a second repeat biopsy after a first negative repeat biopsy could be questioned. Like the study by Gokden et al, 6 our current study failed to reveal a correlation between the length of intervals to repeat biopsy and the likelihood to identify PCa.
Our high cutoff of 4 or more cores involved by HGPIN to define ''widespread'' HGPIN could have potentially accounted for the differences between our findings and those of other studies, 3, 6, 10, 16 including 2 recent studies, 6, 16 showing lack of correlation among number of HGPIN cores and PCa likelihood. In the study by Naya et al, 16 only 4 of their 42 patients would have been diagnosed with widespread HGPIN as defined in the current study. Compared with our study, the mean number of HGPIN cores per biopsy was also lower in the study by Gokden et al 6 (1.3 cores) .
The current study demonstrated an increase likelihood of finding prostate cancer or HGPIN/PINATYP on repeat biopsy after HGPIN in the group of patients who were Z70 years old at the time of their initial biopsy compared with those who were younger. Such a relationship with age has been previously suggested in the study by Godken et al. 6 Although seemingly intuitive, prior studies including one by our group 11, 16 have failed to reveal such a correlation.
The limitations of our study include the retrospective nature of our analysis and the relatively large fraction of patients (32 of 73 patients) who did not undergo a F/U procedure after initial diagnosis of HGPIN. Our finding of statistically significant higher PSA levels, before initial HGPIN biopsy, in the group of patients with F/U biopsy (P = 0.0007) suggests that lower initial PSA levels may have accounted at least in part for the lack of F/U in the 32 patients that were excluded from our analysis. However, given the fact that initial PSA levels in the 41 patients with available F/U biopsy did not correlate with the subsequent likelihood of finding PCa (P = 0.4), it is very unlikely that a ''PSA level selection bias'' is responsible for the high rate of PCa in our group of patients with widespread HGPIN. The lack of statistically significant difference in age or number of initial cores between the 41 study patients and the 32 excluded patients also support the absence of a selection bias. The relatively large number of patients who had widespread HGPIN but lacked F/U could be due, at least in part, to the recent less stringent pattern of F/U recommendations at least in the immediate period after a diagnosis of HGPIN. 13, 14 If confirmed, our findings could potentially readjust that pattern in the subset of patients with widespread HGPIN.
Another limitation is that there may be other situations where a patient would have extensive HGPIN on biopsy yet would not meet our definition of ''widespread HGPIN.'' For example, there are unusual cases where <4 cores are involved by HGPIN yet each core is extensively involved. It remains to be seen whether these cases are also associated with an increased risk of having cancer on repeat biopsy. We chose to use 4 or more cores involved by HGPIN as our definition of widespread HGPIN, as in a prior study of ours we failed to detect differences in the risk of cancer when cases with HGPIN were stratified to 1 versus more than 1 core involved by HGPIN, with most of the cases having 2 cores involved. However, as in our older study we had only 3 men with 3 cores involved, it remains to be studied whether men with 3 cores involved with HGPIN also have an increased risk of cancer on repeat biopsy.
In summary, our study revealed a 39% likelihood of finding PCa in patients with an initial finding of HGPIN on 4 or more cores. This likelihood rate is higher than what is currently expected after a benign initial diagnosis. The likelihood of finding carcinoma seems to be even higher (55%) in patients who are Z70 years old at the time of initial widespread HGPIN diagnosis. Patients with a fewer number of cores on initial biopsy were more likely to be diagnosed with prostate carcinoma on repeat biopsy. The current findings, if validated in future studies, could have implications on F/U recommendations in this subset of patients.
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